Lupin Expands US Market with Generic Diabetes Drug Launch

Lupin has launched a generic version of the diabetes medication Liraglutide Injection in the US. The product, bioequivalent to Novo Nordisk's Victoza, serves as an adjunct to diet and exercise for glycemic control in type 2 diabetes patients. It marks an important expansion in Lupin's injectable drug portfolio.

Lupin, a leading pharmaceutical company, announced on Friday the launch of a generic diabetes drug in the United States market. This move marks a significant step in its effort to expand its complex injectable drug offerings.

Specifically, Lupin has introduced Liraglutide Injection, a 6 mg/mL single-patient-use prefilled pen, that is bioequivalent to Novo Nordisk Inc's Victoza. The medication is indicated for adults and pediatric patients aged ten years and older, as a complement to diet and exercise to manage glycemic levels in type 2 diabetes patients.

According to IQVIA MAT data, this generic medication reached estimated annual sales of USD 350 million in the US market. This launch is described by Spiro Gavaris, Lupin President – US Generics, as a milestone that underscores the company's dedication to improving access to essential therapies.

(With inputs from agencies.)